And yet, even on FR the kill-shot has its defenders...
Bookmark
And yet, even on FR the kill-shot has its defenders...>>>>>>>>>>>>.
Yes. Almost continuously.
I abhor the mandates to get vaxxed . Every one has a choice and has to live or die by it.
The Big Pharm campaign against IVM is related to the fact that it reverses the spike protein over-burden of the blood system, IMHO. The body works hard to rid itself of spike protein, which is why the clot shot only works for a limited period of time,3 to 5 months.
But some of us do not have the ciculatory capability to slowly purge the system of spike proteins, and we then have circulatory complications which effect the heart, brain and lungs by micro clotting and macro clotting. The death is then categorized as caused by stroke or heart attack.
Ivermectin is our friend.It bonds with spike protein chemically and strips it form the system.
Here is the science :
***************************************
How Ivermectin works:
There is reasonably solid evidence that ivermectin docks to the spike protein itself to prevent binding to the ACE2 receptor which is the primary pathology causing the tissue damage and clots related to SARS-CoV-2. Therefore, this is also an implication that this ability of ivermectin to disable the binding of the Spike protein including the vaccine-produced spike proteins. This binding of ivermectin to disable the spike protein is also preserved even with the newer spike protein mutations, but its activity against the original Wuhan spike protein,(the one vaccines were designed to produce) is fairly well studied at this point.
Abstract:
Background/Aim: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). One drug that has attracted interest is the antiparasitic compound ivermectin, a macrocyclic lactone derived from the bacterium Streptomyces avermitilis. We carried out a docking study to determine if ivermectin might be able to attach to the SARS-CoV-2 spike receptor-binding domain bound with ACE2. Materials and Methods: We used the program AutoDock Vina Extended to perform the docking study. Results: Ivermectin docked in the region of leucine 91 of the spike and histidine 378 of the ACE2 receptor. The binding energy of ivermectin to the spike-ACE2 complex was -18 kcal/mol and binding constant was 5.8 e-08.
Conclusion: The ivermectin docking we identified may interfere with the attachment of the spike to the human cell membrane. Clinical trials now underway should determine whether ivermectin is an effective treatment for SARS-Cov2 infection.
******************************